Status:
COMPLETED
Effect of Molecular Hydrogen in Patients With NAFLD
Lead Sponsor:
Comenius University
Collaborating Sponsors:
NWN & Drink HRW
Conditions:
Non-Alcoholic Fatty Liver Disease
Eligibility:
All Genders
33-69 years
Phase:
NA
Brief Summary
Molecular hydrogen H2 acts as antioxidant which selectively reduces cytotoxic harmful reactive oxygen species ROS and concomitantly acts as biological messenger, which mediates several signaling pathw...
Detailed Description
Non-alcoholic fatty liver disease, NAFLD, is the most common cause of liver disease. According to the forecasts, the non-alcoholic steatohepatitis will be the most common cause of liver transplantatio...
Eligibility Criteria
Inclusion
- People with age 33-69 years
- BMI ≥ 25
- Confirmation of fatty liver by ultrasonographic examination
- Signed informed consent
- Alcohol intake according to the AUDIT questionnaire 5 or less points for men or 4 or less points for women
Exclusion
- Unsigned informed consent
- BMI \< 25
- Presence of severe inflammatory disease with activity (Crohn's disease, ulcerative colitis, active tuberculosis, rheumatoid arthritis, etc.)
- Presence of acute infectious disease (acute hepatitis, peritonitis, cholecystitis, pancreatitis, etc.)
- Presence of active neoplastic disease
- Alcohol intake according to the AUDIT questionnaire more as 5 points for men or more as 4 points for women
Key Trial Info
Start Date :
May 1 2020
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 18 2020
Estimated Enrollment :
30 Patients enrolled
Trial Details
Trial ID
NCT05325398
Start Date
May 1 2020
End Date
December 18 2020
Last Update
April 13 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
3rd Department of Internal Medicine Faculty of Medicine Comenius University in Bratislava
Bratislava, Slovakia, 83101